Prostate Biopsy Report Explained
A prostate biopsy report confirms whether prostate cancer is present and describes features that help estimate its aggressiveness. The most important terms are Gleason pattern, Gleason score and ISUP Grade Group (1 to 5), along with how many biopsy cores contain cancer and how much of each core is involved. The report may also mention perineural invasion, cribriform or intraductal carcinoma and other histological features. A biopsy report should be interpreted with PSA, MRI findings and clinical stage—Grade Group alone does not tell you whether the cancer has spread.
Gleason score and Grade Group
- Grade Group 1: Gleason 3+3=6
- Grade Group 2: Gleason 3+4=7
- Grade Group 3: Gleason 4+3=7
- Grade Group 4: Gleason 8
- Grade Group 5: Gleason 9-10
Why 3+4 is different from 4+3
The first Gleason number is the dominant pattern. Pattern 4 is more aggressive than pattern 3, so 4+3 disease has a higher proportion of aggressive architecture than 3+4 and is placed in a higher Grade Group.
Cores, percentage involvement and tumour volume
The report lists how many systematic and targeted cores are positive, the length or percentage of cancer in each, and sometimes the percentage of pattern 4. These details help distinguish a small low-volume cancer from more extensive disease within the same Grade Group.
Other terms you may see
Perineural invasion means cancer is seen tracking around a nerve within the biopsy; it does not by itself prove spread outside the prostate. Cribriform architecture and intraductal carcinoma are adverse features that can influence management. Extraprostatic extension in a biopsy core, when present, is important for staging.
What happens after a positive biopsy?
PSA, MRI, Grade Group, core burden and clinical stage are combined into a risk group. Staging with PSMA PET may be recommended for higher-risk disease. Options may include active surveillance, surgery, radiotherapy or systemic/multimodal therapy depending on risk and patient factors.
The most important line is not “adenocarcinoma present”
A useful prostate-biopsy report should specify Grade Group/Gleason score, number of positive cores, percentage or length of involvement, laterality and adverse features such as cribriform or intraductal carcinoma when present. These details help distinguish surveillance-appropriate disease from cancer that is more likely to need definitive treatment.
Gleason 3+4 is not the same as 4+3
Both add to 7, but the predominant pattern differs. Grade Group 2 (3+4) generally behaves more favourably than Grade Group 3 (4+3), particularly when the amount of pattern 4 is small. This is one reason patients should know the actual pattern rather than only the total score.
Targeted and systematic cores must be read together
MRI-targeted cores can show the worst lesion, while systematic cores sample the rest of the gland. Treatment planning considers both. A pathology review can be useful when a borderline Grade Group or unusual subtype would change eligibility for active surveillance or treatment intensity.
Four lines in the pathology report drive most decisions
Look for the cancer type, Grade Group/Gleason pattern, number or proportion of positive cores, and the amount of tumour in each core. The report may also mention cribriform or intraductal carcinoma, perineural invasion or other features that affect risk interpretation. A biopsy samples the prostate rather than mapping every millimetre, so MRI and PSA density remain relevant when the pathology seems unexpectedly low or high compared with the rest of the case.
When to seek earlier medical review
Ask for pathology review when Grade Group, core involvement or special features appear discordant with MRI/PSA, or when the report contains terms you do not understand. Fever or urinary retention after biopsy requires urgent medical care.
Emergency warning signs
- Inability to pass urine
- New severe back pain with leg weakness, numbness or loss of bladder/bowel control
- Severe bleeding after biopsy or inability to pass urine
- Fever or chills after prostate biopsy
What to bring to your consultation
- Full biopsy pathology report
- MRI report/images
- PSA and prostate volume/PSA density if available
- Previous biopsy report for comparison
Questions to ask your doctor
- What is the highest Grade Group and how much pattern 4 is present?
- How many systematic and targeted cores are involved?
- Are cribriform or intraductal features reported?
FAQs
Does Gleason 6 mean “6 out of 10” cancer?
No. Contemporary prostate cancer grading starts at Gleason 6 for Grade Group 1; it is the lowest grade generally called cancer on biopsy.
Is 3+4 the same as 4+3?
No. Both sum to 7, but 4+3 is Grade Group 3 and generally behaves more aggressively than 3+4 (Grade Group 2).
What does a negative biopsy mean if MRI is suspicious?
It lowers the likelihood of clinically significant cancer but does not eliminate it. MRI-targeting quality, lesion location, PSA density and follow-up determine whether repeat evaluation is needed.
Should biopsy slides ever be reviewed again?
Expert pathology review can be useful when the diagnosis or grade will significantly change a major treatment decision.
Related reading
- Prostate Cancer: Symptoms, Diagnosis and Treatment
- PSA Test for Prostate Cancer
- Prostate MRI Explained
- Prostate Cancer Stages Explained
- Transperineal vs Transrectal Prostate Biopsy
- MRI Fusion Prostate Biopsy Explained
- Kidney Mass Biopsy: When Is It Needed?
- Urologist in Latur
References
- European Association of Urology (EAU). Prostate Cancer Guidelines, 2026. Diagnostic Evaluation https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation
- European Association of Urology (EAU). Prostate Cancer Guidelines, 2026. Treatment https://uroweb.org/guidelines/prostate-cancer/chapter/treatment
- National Cancer Institute. Prostate Cancer Treatment (PDQ) – Patient Version https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq